Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Eupraxia Pharmaceuticals yesterday and set a price target of $19.00. The company’s shares closed yesterday at C$10.04.

End of Quarter Sale - 50% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Kluska is a 5-star analyst with an average return of 22.3% and a 42.72% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Eupraxia Pharmaceuticals, Soleno Therapeutics, and DBV Technologies SA – American.

Eupraxia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $14.80, representing a 47.44% upside. In a report released on March 25, Bloom Burton also maintained a Buy rating on the stock with a $14.00 price target.

Based on Eupraxia Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of C$23.3 million. In comparison, last year the company had a GAAP net loss of C$10.8 million

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.